A practical reference on Cyclic AMP: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-18. Anything still debated is marked as such rather than presented as settled.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
=== Trapping === In the Orbitrap, ions are trapped because their electrostatic attraction to the inner electrode is balanced by their inertia. Thus, ions cycle around the inner electrode on elliptical trajectories. In addition, the ions also move back and forth along the axis of the central electrode so that their trajectories in space resemble helices. Due to the properties of the quadro-logarithmic potential, their axial motion is harmonic, i.e. it is completely independent not only of motion around the inner electrode but also of all initial parameters of the ions except their mass-to-charge ratios m/z. Its angular frequency is: ω = √k/(m/z), where k is the force constant of the potential, similar to the spring constant.
Michael Bailey, who found that homosexuality had a genetic possibility; Laura Allen and Roger Gorski of UCLA had conducted research on the anterior commissure; molecular geneticist Cassandra Smith; the editor of The Arizona Republic. Directed by Jeremy Taylor, produced by Oliver Morse, made by Windfall Films 18 October Antichaos, about order out of chaos, with Ian Stewart of the University of Warwick; Canadian mathematician Brian Goodwin of the Open University, and emergence; the American biologist Stuart Kauffman of the Santa Fe Institute, and Boolean networks; the Danish theoretical physicist Per Bak of Brookhaven National Laboratory; Christopher Langton of the Santa Fe Institute; the American ecologist Tom Ray of the University of Delaware; the economist W. Brian Arthur of Stanford University; J. Doyne Farmer of the Prediction Company; and the American physicist Thomas Valone (a writer on bioelectromagnetics) of the University of New Mexico. Narrated by Alun Lewis, directed by Yavar Abbas, produced by Geoff Deehan, made by Union Pictures 25 October The Strange Case of Crop Circles 2, showing what had changed from the previous documentary broadcast on 27 October 1991. Directed by Jill Freeman, produced by Michael Wills, made by Juniper Productions 1 November Zen on Wheels, about how Japanese car manufacturers moved a team to Newport Beach, California at the Toyota Calty Design Research, to find out what appealed to buyers of BMW and Mercedes cars, which resulted in the Lexus LS, which outsold Mercedes-Benz and BMW.
== Sample collection == There are no set rules for sample selection in detrital zircon geochronology studies. The objective and scale of the research project govern the type and number of samples taken. In some cases, the sedimentary rock type and depositional setting can significantly affect the result. Examples include:
Sources: en.wikipedia.org
=== Polysaccharide chiral stationary phases === The naturally occurring polysaccharide form the basis for an important group of columns designed for chiral separation. The main polysaccharides are cellulose, amylose, chitosan, dextran, xylan, curdlan, and inulin. Polysaccharide-based stationary phase have a high loading capacity, many chiral centers and complicated stereochemistry, and can be used for the separation of a wide range of compounds. Polysaccharide-based chiral stationary phases have a wide application due to their high separation efficiency, selectivity, sensitivity and reproducibility under normal and reversed-phase conditions, as well as their broad applicability for structurally diversified compounds. The mechanism of chiral interaction on the polysaccharide-based chiral stationary phase has not yet been elucidated. However, the following interactions are believed to play a role in the retention: (i) Hydrogen bonding interactions of the polar chiral analyte with carbamate groups on the CSP; (ii) π-π interactions between phenyl groups on the CSP and aromatic groups of the solute; (i) Dipole-dipole interactions (ii) Steric interactions due to the helical structure of the CSP. These effects on the retention process originate also from the functionality of the derivatives of the polysaccharide, its average molecular weight, and size distribution, the solvent used to immobilize it on the macroporous silica support, and the nature of the macroporous silica support itself.
=== Nematode === The genome of the nematode worm C. elegans contains 9 serpins, all of which lack signal sequences and so are likely intracellular. However, only 5 of these serpins appear to function as protease inhibitors. One, SRP-6, performs a protective function and guards against stress-induced calpain-associated lysosomal disruption. Further, SRP-6 inhibits lysosomal cysteine proteases released after lysosomal rupture. Accordingly, worms lacking SRP-6 are sensitive to stress. Most notably, SRP-6 knockout worms die when placed in water (the hypo-osmotic stress lethal phenotype or Osl). It has therefore been suggested that lysosomes play a general and controllable role in determining cell fate.
On January 6, 2021, following the U.S. Capitol attack, Bush denounced the violence and attack alongside the three other living former presidents, Obama, Clinton, and Carter, releasing a statement saying that "this is how election results are disputed in a banana republic, not our democratic republic", and that "it is a sickening and heartbreaking sight". He also echoed president-elect Biden's message saying that what occurred at the Capitol was an "insurrection". On January 20, Bush and his wife attended Biden's inauguration. Bush opposed President Biden's withdrawal of American troops from Afghanistan, saying that the withdrawal made him "concerned" and that it had the potential to "create a vacuum, and into that vacuum is likely to come people who treat women as second-class citizens". During an interview with Deutsche Welle on July 14, 2021, Bush reaffirmed his opposition to the troop withdrawal, calling the plan "a mistake". On September 11, 2021, the 20th anniversary of the September 11 attacks, Bush gave a speech at the Flight 93 National Memorial, praising the heroism of the people on Flight 93 and the spirit of America. He also said that he "saw millions of people instinctively grab for a neighbor's hand and rally to the cause of one another. That is the America I know." Bush condemned the assassination attempt on then-former president Trump, who was the presumptive Republican nominee, on July 13, 2024, calling it "cowardly" and applauding the Secret Service's response.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.